Drugs / DSP-9632P
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05435729 | May → Nov 2022 | Parkinson disease, drug-induced dyskinesia | Sumitomo Pharma Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DSP-9632P | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05435729 ↗ |
| Route | Other | “single transdermal dose of DSP-9632P” NCT05435729 ↗ |